ETRAElectra Therapeutics, Inc.

🇺🇸 US
7.99
USD
Analysis Scores
Lothien Robustness Score?
39/100
Weak
Neden bu skor?
Damodaran ?
-
Damodaran skoru hesaplanamadı
Dalio Risk ?
65/100
Piotroski ?
4/9
Neutral
gross profit, revenue, prev year gross profit data missing → margin comparison unavailable (C8)
Graham ?
Veri Yetersiz
Özkaynaklar negatif veya sıfır — Graham formülü pozitif defter değeri gerektirir
Lothien Robustness Summary
39/100
Lothien Sağlamlık: Zayıf (39/100)
Olumsuz göstergeler ağır basıyor. Finansal yapıda zayıflıklar mevcut. | Kısa Vade: Nötr | Uzun Vade: Nötr | Pozitif: 2 | Negatif: 3 | Nötr: 1
Net Zarar
Son çeyrekte -$15M zarar açıklandı. Yatırımcı dikkatli olmalı.
Kâr Stabil
Net kâr bir önceki çeyreğe göre fazla değişmedi (%+0.0). İstikrarlı seyir.
Yıllık Kâr Geriledi
Geçen yılın aynı dönemine göre net kâr %-150.0 düştü. Uzun vadede endişe verici.
Net Nakit Pozisyonu
Şirketin nakdi borçlarından $31M fazla. Borç riski düşük.
Güçlü Likidite
Cari oran 9.82x — kısa vadeli borçları rahat karşılıyor.
Sonraki Çeyrek: Düşüş Beklentisi
Tahminine göre kâr %-28.9 düşebilir. Sonraki bilançoya dikkat.

Data date 2026-11-10 Not investment advice; the figures are rule-based model output. How the scores are computed

Score record
Data date 2026-11-10
Update frequency Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run

Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.

AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.

Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.

WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.

Model output; not investment advice; different models can disagree. Report an error

Risk Analysis (VaR) Çok Yüksek
38 days
Annual Volatility ?
%72.8
VaR 95% ?
%8.76
daily max loss
VaR 99% ?
%11.88
daily max loss
CVaR 95% ?
%8.77
expected loss (tail)
Max Drawdown ?
%47.5
21.09.2026 → 02.11.2026
Skewness ?
0.30
Parametrik%8.76
Historik%7.64
Cornish-Fisher%8.39
Return Distribution
Valuation
Potential?
-
Debt Cycle?
Early Expansion
Balance Sheet Analysis? Q2026/9
Son 5 çeyrek ardışık zarar
Fiyat TRAMA-99 hafif altında: %+0.0
Direnç seviyesi: TRAMA-99 = 7.99 USD
Fundamental & Technical Analysis
Profitability
ROE - Return on Equity (TTM) %51.1
ROE %51.1 — high return on equity.
Valuation
No sector data
Indebtedness
Current Ratio 7.37x
Current ratio 7.37x — current assets are 2x short-term liabilities. Very healthy liquidity.
Interest Coverage -469.2x
Interest coverage -469.2x — critical level. Risk of difficulty in interest payments.
Growth
Net Profit Growth (YoY) %-150.0
Loss %150.0 increased — losses deepening.
Score Explanations
Lothien Robustness
39/100
Weak robustness (39/100). Valuation metrics and/or debt profile are unfavorable; caution is needed.
Weak
Dalio Risk Analysis
65/100
Moderate debt risk (65/100). Interest coverage ratio -469.2x — weak, fragile.
Leverage: 50/100 | Debt Service: 100/100 | Quality: 44/100
Debt Cycle Phase
Early Expansion
Debt decreasing, growth gaining momentum. Company in balance sheet cleanup phase.
Piotroski F-Score
4/9
Weak Piotroski (4/9). Many balance sheet quality criteria not met. Note: gross profit, revenue, prev year gross profit data missing → margin comparison unavailable (C8)
Neutral
Graham Intrinsic Value
—
↔
TRAMA-99 Trend — Near TRAMA
Price (7.99), TRAMA-99 line (7.99) at close levels (%+0.0). Important decision zone — breakout direction will determine the trend.
Price:: 7.99
TRAMA: 7.99
Difference: %+0.0
Charts
Indicators
BB deviation ?
RSI thresholds ?

Price Chart ?
▲ içeriden alım · ▼ içeriden satım · ★ katalizör (haber-sezgisel) · ■ 13D aktivist · ■ 13G pasif — SEC Form 4 ~2 gün gecikmeli, yalnız yönetici/direktör/%10+ sahip; katalizör = haber-sezgisel; 13D/G = %5+ pay bildirimi ~5 iş günü gecikmeli.
RSI (14) ?
Bollinger Bands ?
MACD ?

İçeriden Alım-Satım Akışı

Kim aldı, kim sattı, ne kadar

ETRA — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.